Karolinska Development divests its holding in the Danish dermatology company Henlez
September 23 2024 - 10:26AM
UK Regulatory
Karolinska Development divests its holding in the Danish
dermatology company Henlez
STOCKHOLM, SWEDEN, September 23 2024. Karolinska Development AB
(Nasdaq Stockholm: KDEV) announces the divestment of all its shares
in the portfolio company Henlez ApS. Following the transaction,
Karolinska Development's investment portfolio consists of eleven
holdings.
Karolinska Development invested in Henlez ApS in 2022, in
syndication with the Nordic venture capital firm Eir Ventures.
Henlez is a privately held Danish dermatology company focused on
hidradenitis suppurativa.
Prior to the divestment, Karolinska Development's ownership in
Henlez amounted to 15 %.
For further information, please contact:
Viktor Drvota, CEO, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail:
viktor.drvota@karolinskadevelopment.com
Johan Dighed, General Counsel and Deputy CEO, Karolinska
Development AB
Phone: +46 70 207 48 26, e-mail:
johan.dighed@karolinskadevelopment.com
TO THE EDITORS
About Karolinska Development AB
Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life
sciences investment company. The company focuses on identifying
breakthrough medical innovations in the Nordic region that are
developed by entrepreneurs and leadership teams. The Company
invests in the creation and growth of companies that advance these
assets into commercial products that are designed to make a
difference to patients’ lives while providing an attractive return
on investment to shareholders.
Karolinska Development has access to world-class medical
innovations at the Karolinska Institutet and other leading
universities and research institutes in the Nordic region. The
Company aims to build companies around scientists who are leaders
in their fields, supported by experienced management teams and
advisers, and co-funded by specialist international investors, to
provide the greatest chance of success.
Karolinska Development has a portfolio of eleven companies
targeting opportunities in innovative treatment for
life-threatening or serious debilitating diseases.
The Company is led by an entrepreneurial team of investment
professionals with a proven track record as company builders and
with access to a strong global network.
For more information, please visit
www.karolinskadevelopment.com
Karolinska Development Ab (LSE:0P3C)
Historical Stock Chart
From Oct 2024 to Nov 2024
Karolinska Development Ab (LSE:0P3C)
Historical Stock Chart
From Nov 2023 to Nov 2024
